Akebia Therapeutics (AKBA) Competitors

Akebia Therapeutics logo
$2.11 +0.01 (+0.48%)
Closing price 04:00 PM Eastern
Extended Trading
$2.12 +0.01 (+0.24%)
As of 07:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

AKBA vs. APGE, WVE, SDGR, BLTE, IOVA, IRON, GPCR, INDV, AMPH, and TVTX

Should you be buying Akebia Therapeutics stock or one of its competitors? The main competitors of Akebia Therapeutics include Apogee Therapeutics (APGE), Wave Life Sciences (WVE), Schrödinger (SDGR), Belite Bio (BLTE), Iovance Biotherapeutics (IOVA), Disc Medicine (IRON), Structure Therapeutics (GPCR), Indivior (INDV), Amphastar Pharmaceuticals (AMPH), and Travere Therapeutics (TVTX). These companies are all part of the "pharmaceutical products" industry.

Akebia Therapeutics vs.

Akebia Therapeutics (NASDAQ:AKBA) and Apogee Therapeutics (NASDAQ:APGE) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, community ranking, media sentiment, dividends, institutional ownership, valuation and profitability.

Akebia Therapeutics received 391 more outperform votes than Apogee Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Apogee Therapeutics an outperform vote while only 63.51% of users gave Akebia Therapeutics an outperform vote.

CompanyUnderperformOutperform
Akebia TherapeuticsOutperform Votes
416
63.51%
Underperform Votes
239
36.49%
Apogee TherapeuticsOutperform Votes
25
100.00%
Underperform Votes
No Votes

33.9% of Akebia Therapeutics shares are owned by institutional investors. Comparatively, 79.0% of Apogee Therapeutics shares are owned by institutional investors. 4.1% of Akebia Therapeutics shares are owned by insiders. Comparatively, 36.1% of Apogee Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Apogee Therapeutics has a net margin of 0.00% compared to Akebia Therapeutics' net margin of -27.07%. Akebia Therapeutics' return on equity of 0.00% beat Apogee Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Akebia Therapeutics-27.07% N/A -20.57%
Apogee Therapeutics N/A -21.81%-20.94%

Akebia Therapeutics currently has a consensus price target of $7.50, suggesting a potential upside of 256.29%. Apogee Therapeutics has a consensus price target of $89.71, suggesting a potential upside of 164.44%. Given Akebia Therapeutics' higher possible upside, equities research analysts plainly believe Akebia Therapeutics is more favorable than Apogee Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Akebia Therapeutics
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Apogee Therapeutics
0 Sell rating(s)
0 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
3.00

In the previous week, Apogee Therapeutics had 7 more articles in the media than Akebia Therapeutics. MarketBeat recorded 11 mentions for Apogee Therapeutics and 4 mentions for Akebia Therapeutics. Akebia Therapeutics' average media sentiment score of 1.30 beat Apogee Therapeutics' score of 0.17 indicating that Akebia Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Akebia Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Apogee Therapeutics
2 Very Positive mention(s)
1 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Akebia Therapeutics has a beta of 0.74, meaning that its share price is 26% less volatile than the S&P 500. Comparatively, Apogee Therapeutics has a beta of 2.18, meaning that its share price is 118% more volatile than the S&P 500.

Akebia Therapeutics has higher revenue and earnings than Apogee Therapeutics. Apogee Therapeutics is trading at a lower price-to-earnings ratio than Akebia Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Akebia Therapeutics$194.62M2.36-$51.92M-$0.23-9.15
Apogee TherapeuticsN/AN/A-$83.99M-$2.42-14.02

Summary

Akebia Therapeutics beats Apogee Therapeutics on 9 of the 16 factors compared between the two stocks.

Get Akebia Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for AKBA and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

AKBA vs. The Competition

MetricAkebia TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$459.27M$6.89B$5.69B$9.02B
Dividend YieldN/A2.91%5.32%4.00%
P/E Ratio-9.159.2388.8019.29
Price / Sales2.36307.871,019.3675.13
Price / CashN/A75.4646.0938.87
Price / Book-13.165.485.054.99
Net Income-$51.92M$123.50M$113.53M$222.83M
7 Day Performance-3.00%-4.89%-1.49%-0.86%
1 Month Performance20.29%-2.48%3.24%2.55%
1 Year Performance29.94%1.49%20.85%17.62%

Akebia Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
AKBA
Akebia Therapeutics
4.2116 of 5 stars
$2.11
+0.5%
$7.50
+255.5%
+28.0%$460.36M$194.62M-9.17430Analyst Upgrade
Short Interest ↓
Gap Down
APGE
Apogee Therapeutics
2.4601 of 5 stars
$40.54
-2.0%
$89.71
+121.3%
-3.8%$1.83BN/A-16.7591Analyst Forecast
News Coverage
WVE
Wave Life Sciences
4.2957 of 5 stars
$11.86
+2.5%
$22.22
+87.3%
+153.9%$1.81B$113.31M-10.69240Gap Down
SDGR
Schrödinger
2.1481 of 5 stars
$24.72
-1.4%
$32.11
+29.9%
-11.2%$1.80B$193.35M-10.56790Gap Down
BLTE
Belite Bio
3.2962 of 5 stars
$57.72
-0.6%
$96.33
+66.9%
+20.0%$1.78BN/A-52.0010Short Interest ↓
IOVA
Iovance Biotherapeutics
4.1421 of 5 stars
$5.64
-3.6%
$22.69
+302.3%
-42.4%$1.72B$1.19M-3.79500
IRON
Disc Medicine
2.1594 of 5 stars
$54.99
-1.5%
$88.90
+61.7%
-20.8%$1.64BN/A-13.8230Short Interest ↑
Analyst Revision
GPCR
Structure Therapeutics
2.4944 of 5 stars
$28.44
-5.1%
$81.29
+185.9%
-49.4%$1.63BN/A-38.43136Short Interest ↓
INDV
Indivior
2.7916 of 5 stars
$11.73
-1.4%
$16.00
+36.4%
-43.1%$1.62B$1.09B-293.181,164Short Interest ↑
News Coverage
Positive News
AMPH
Amphastar Pharmaceuticals
4.7016 of 5 stars
$33.43
-4.1%
$60.33
+80.5%
-42.1%$1.61B$644.40M11.141,761Short Interest ↓
TVTX
Travere Therapeutics
2.3552 of 5 stars
$20.25
-1.0%
$24.00
+18.5%
+180.1%$1.58B$145.24M-4.45460Analyst Forecast
Insider Trade
News Coverage

Related Companies and Tools


This page (NASDAQ:AKBA) was last updated on 2/12/2025 by MarketBeat.com Staff
From Our Partners